Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Biosyent Inc
V.RX
Alternate Symbol(s):
BIOYF
Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing...
biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:RX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Mar 10, 2022 8:55am
RE:Return to Glory Days
Beat Bloom Burton's forecast of $26.9 mil rev, $7.9 mil ebitda, $0.39 eps.
(86)
•••
theinvestor22
X
View Profile
View Bullboard History
Comment by
theinvestor22
on Mar 09, 2022 9:27pm
RE:Return to Glory Days
Yup, that was quite a good quarter. I can only imagine how well the company will do once they get full access to health care professionals once again. Kudos to RX mgmt. And, I think a
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Mar 09, 2022 7:07pm
RE:Return to Glory Days
Long time coming.... Revenue eps 2021 28,618,218 $0.49
...more
(24)
•••
overnout
X
View Profile
View Bullboard History
Post by
overnout
on Mar 09, 2022 4:41pm
Return to Glory Days
MISSISSAUGA, Ontario, March 09, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months
...more
(24)
•••
overnout
X
View Profile
View Bullboard History
Post by
overnout
on Mar 09, 2022 8:50am
Earnings After Close Today
MISSISSAUGA, Ontario, March 03, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three
...more
(24)
•••
overnout
X
View Profile
View Bullboard History
Post by
overnout
on Feb 14, 2022 9:02am
Interesting New By-Law
MISSISSAUGA, Ontario, Feb. 11, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that its Board of Directors has approved the
...more
(9750)
•••
Karren411
X
View Profile
View Bullboard History
Comment by
Karren411
on Jan 14, 2022 1:24pm
RE:Normal Course Issuer Bid - Continues
(24)
•••
overnout
X
View Profile
View Bullboard History
Comment by
overnout
on Dec 14, 2021 8:16am
RE:RE:Normal Course Issuer Bid - Continues
Maybe we'll be down to 5 million shares when they pay the special dividend of $1. Won't cost them so much
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 13, 2021 1:23pm
RE:Normal Course Issuer Bid - Continues
Zzzzzzzzzzzzz
(24)
•••
overnout
X
View Profile
View Bullboard History
Post by
overnout
on Dec 13, 2021 9:33am
Normal Course Issuer Bid - Continues
MISSISSAUGA, Ontario, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange
...more
(13075)
•••
SusanBolland
X
View Profile
View Bullboard History
Comment by
SusanBolland
on Dec 02, 2021 5:02am
RE:Expect a Dividend from BioSyent Next Year
(0)
•••
ZakDixon
X
View Profile
View Bullboard History
Post by
ZakDixon
on Nov 19, 2021 12:12pm
Expect a Dividend from BioSyent Next Year
BioSyent Management is averse to promoting its own share price. It does not give future guidance and won't say anything positive about the share although it may be considering. The CEO, Rene
...more
(0)
•••
ZakDixon
X
View Profile
View Bullboard History
Post by
ZakDixon
on Nov 19, 2021 12:11pm
BioSyent Q3 Results
BioSyent Inc. is on a trajectory to grow double digit over the next few years. It is very conservative with capital deployment but suspect with the $27 million in cash it is going to be forced to
...more
(86)
•••
theinvestor22
X
View Profile
View Bullboard History
Comment by
theinvestor22
on Nov 19, 2021 9:12am
RE:Dividend ?
They actually mentioned it in passing last quarter as well, but that was the first time I'd heard it. I think they said they'd consider it if they couldn't find another productive
...more
(5)
•••
Awarded
X
View Profile
View Bullboard History
Post by
Awarded
on Nov 19, 2021 12:05am
Dividend ?
Interesting. The company has traditionally used excess cash to buy back shares. This quarter is the first time I can recall a mention of distributing dividends
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >